Back to top

[ Skip to main content ]

The passing of world leading legislation on new psychoactive substances takes New Zealand a big step closer to healthy drug law, the New Zealand Drug Foundation said today.

“The Psychoactive Substances Act is a world first at getting ahead of the ‘legal highs’ industry and taking control of the problems these substances cause,” New Zealand Drug Foundation Executive Director Ross Bell said.

The law, which passed its final reading in Parliament today, sets up a regulatory framework where manufacturers of products like synthetic cannabis will have to prove they are ‘low risk’ before the can be sold. It also imposes restrictions on who can make and sell the substances as well as measures to reduce availability.

“This is a cutting edge and pragmatic approach to new psychoactive substances which will reduce the harm they cause in our communities,” Mr Bell said.

“It is fantastic that the Government has listened to community concerns, acted on the evidence and built consensus on the best way to handle this complicated area of policy.”

Mr Bell said that the regulation of new psychoactive substances was the first step in the right direction for healthy drug law.

“New Zealand now needs to implement broader health-focussed changes to our outdated drug laws.”

The Psychoactive Substances Act key points

  • Sets up a legal framework for the testing, manufacture, sale and regulation of psychoactive products.
  • Includes health and harm minimisation in the purpose of the act.
  • Products will no longer be sold in dairies, grocery stores etc. People and businesses will need a license to sell the products.
  • Restrictions on advertising and marketing and the purchase age (18+)
  • Like alcohol, councils will have the option of developing local policies around where stores can be located.
  • Products will undergo rigorous clinical testing to determine whether they are ‘low risk’.
  • Clear rules around use of animal testing. Animal testing can only be used if there is no alternative.
  • If proven a product is ‘low risk’ of harm then as long as a person meets certain criteria (e.g. person of good repute, NZ citizen) a three year licence to sell that product can be granted.
  • Products which appear to cause more harm than clinical testing showed can be pulled from the market.
  • A register of all approved and unapproved products will be publically available.
  • A code of practice will be in place within 6 months.
Share:

Check out these related articles: See more articles on Drug law reform

Roadside drug tests – There's no simple solution to this complex issue

The Drug Foundation has urged the government to listen to the evidence before acting on calls for roadside testing....

Read More

Misuse of Drugs amendment: A temporary fix while we address the real problem

MPs are currently hearing public submissions on a potentially significant change to our drug law - the Misuse of Drugs Amendment Bill. Here'......

Read More

Drug Foundation is backing a Yes vote

Following the announcement of the Government’s approach to the 2020 cannabis referendum, the Drug Foundation will be promoting a Yes vote....

Read More
MoS march 2019 thumbnail menatal health inq

Mental Health Inquiry: Change of direction needed

The Mental Health and Addictions Inquiry signalled a major direction change but provided no navigation rules. Who should plot the new course......

Read More
e substance newsletter promotional thumbnail

Subscribe to email updates

Get regular news, analysis and commentary on drugs issues in New Zealand. Free.

Sign up now!

Did You Know resources thumbnail

Did You Know: Teenagers can handle facts about drugs

Young people are more likely to delay or not use alcohol or other drugs if they know the facts about specific substances. Use our age-appropriate tools to start conversations with whānau and your young person... a-sap!

Learn more